A Multi-arm Phase I Trial of Hepatic Arterial Infusion of Irinotecan With 1) Systemic Bevacizumab 2) Systemic Bevacizumab and Oxaliplatin 3) Systemic Bevacizumab and Cetuximab in Patients With Advanced Solid Tumors Metastatic to the Liver

Trial Profile

A Multi-arm Phase I Trial of Hepatic Arterial Infusion of Irinotecan With 1) Systemic Bevacizumab 2) Systemic Bevacizumab and Oxaliplatin 3) Systemic Bevacizumab and Cetuximab in Patients With Advanced Solid Tumors Metastatic to the Liver

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Sep 2015

At a glance

  • Drugs Irinotecan (Primary) ; Bevacizumab; Cetuximab; Oxaliplatin
  • Indications Cancer metastases; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Feb 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.
    • 12 Feb 2014 According to the ClinicalTrials.gov record, status changed from completed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top